Open AccessEfficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
Author(s) -
Anıl Tombak,
Funda Pepedil Tanrıkulu,
Salih Sertaç Durusoy,
Hüseyin Derya Dinçyürek,
Emin Kaya,
Elif Gülsüm Ümit,
İrfan Yavaşoğlu,
Özgür Mehtap,
Burak Devecı,
Mehmet Ali Özcan,
Hatice Terzi,
Müfide Okay,
Nilgün Sayınalp,
Mehmet Yılmaz,
Vahap Okan,
Alperen Kizikli,
Ömer Özcan,
Güven Çetin,
Si̇nan Demi̇rci̇oğlu,
İsmet Aydoğdu,
Güray Saydam,
Eren Arslan Davulcu,
Gül İlhan,
Mehmet Ali Uçar,
Gülsüm Özet,
Seval Akpınar,
Burhan Turgut,
İlhami Berber,
Erdal Kurtoğlu,
Mehmet Sönmez,
Derya Selim Batur,
Rahşan Yıldırım,
Vildan Özkocamaz,
Ahmet Kürşad Güneş,
Birsen Sahip,
Şehmus Ertop,
Olga Meltem Akay,
Abdülkadir Baştürk,
Mehmet Hilmi Doğu,
Aydan Akdeniz,
Ali Ünal,
Ahmet Şeyhanlı,
Emel Gürkan,
Demet Çekdemir,
Burhan Ferhanoğlu
Publication year - 2021
Publication title -
turkish journal of hematology
Language(s) - English
Resource type - Journals
ISSN - 1300-7777
DOI - 10.4274/tjh.galenos.2021.2021.0007
Subject(s) - medicine , ibrutinib , retrospective cohort study , confidence interval , oncology , leukemia , chronic lymphocytic leukemia , surgery
This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients.